USANA Health Sciences (USNA) Receives News Impact Score of 0.07

Media stories about USANA Health Sciences (NYSE:USNA) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. USANA Health Sciences earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0375115489445 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

A number of equities analysts recently issued reports on the company. BidaskClub upgraded USANA Health Sciences from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Pivotal Research lifted their target price on USANA Health Sciences from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, October 25th.

USANA Health Sciences (USNA) opened at $70.45 on Friday. The stock has a market capitalization of $1,690.00, a price-to-earnings ratio of 19.09 and a beta of 1.07. USANA Health Sciences has a 1-year low of $52.55 and a 1-year high of $72.80.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.11. The business had revenue of $261.77 million for the quarter, compared to analysts’ expectations of $259.52 million. USANA Health Sciences had a return on equity of 26.38% and a net margin of 8.79%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.40 EPS. research analysts forecast that USANA Health Sciences will post 3.7 EPS for the current year.

In other news, Director Myron W. Wentz sold 34,226 shares of USANA Health Sciences stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $57.51, for a total transaction of $1,968,337.26. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Myron W. Wentz sold 28,788 shares of USANA Health Sciences stock in a transaction on Friday, September 15th. The shares were sold at an average price of $57.19, for a total value of $1,646,385.72. The disclosure for this sale can be found here. Insiders sold a total of 846,060 shares of company stock worth $54,232,222 over the last 90 days. Insiders own 53.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/12/02/usana-health-sciences-usna-receives-news-impact-score-of-0-07.html.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply